DMC Biotechnologies
Revolutionizing the specialty chemical industry by offering sustainable, bio-based ingredients
Director of Analytical Chemistry and Upstream Bioprocess (APR. 2024 – March 2026)
● Oversaw a 14-member cross-functional organization spanning Analytical, Lab Automation, Bioinformatics, and Fermentation, including 8 direct reports and indirect leadership; served as hiring manager for 2 roles
● Drove analytical strategy and upstream process development for 10 small molecule programs, supporting progression from bench development to 75 L in-house fermentation and CMO scale-up to 50 m³
● Collaborated with executive leadership to align technical execution with business priorities, translating program goals into operational plans, timelines, and resource allocations
● Shaped phase-appropriate quality and regulatory readiness strategy, overseeing external release testing and a multi-year stability program aligned with USP/EP/JP compendial standards
● Managed laboratory ops including capacity and head count planning, instrument lifecycle management, procurement, and workflow prioritization to align resources with milestones and business objectives
● Rebuilt and stabilized the Analytical Chemistry function through strategic recruitment, cultural transformation, and implementation of quality-driven operating frameworks
● Improved first-time-right performance to over 95% and reduced turnaround time to same-week analysis for (U)HPLC, LC-MS/MS, and plate-based assays
● Architected integrated workflow and data systems, including automated analytics, control charting, centralized data platforms, and AI-enabled process standardization to improve scalability and data integrity
● Standardized R&D operations across departments by launching cross-functional governance initiatives and modernizing SOP infrastructure (codified 87 processes), strengthening compliance and audit readiness
● Designed and implemented structured performance management and career development frameworks, supporting 4 promotions, manager development, and leadership pipeline growth
● Oversaw an AI/LLM integration roadmap to standardize R&D processes, unify data systems, and enable scalable cross-functional analytics
KBI Biopharma
Managed and developed a team of CDMO research associates and scientists responsible for analytical testing of bioprocess development samples
SCIENTIST II (APR. 2023 – Present)
● Experienced in executing and developing methods to assess purity (SEC & RP-HPLC, Capillary Electrophoresis, charge heterogeneity (IEX-HPLC, icIEF), impurities (HCP & ProA ELISAs, DNA), titer (affinity HPLC), and glycan profiles (HILIC-UPLC-FLR)
● Lead analytical support for biological programs (MAbs and Fusion proteins) in both early phase (first in human) and late phase (Phase II to PPQ readiness)
● Authored and reviewed protocols, test methods, reports, data summaries and controlled documents in accordance with ICH guidelines and cGMP regulations
● Interfaced with pharmaceutical clients, upstream and downstream product development, and GMP manufacturing to ensure program deliverables and timelines were met
● Expedited timelines by improving data workflows (developed automated assay templates and data analysis reports) and standardized documentation (developed and trained company leads on automated data summary reports created using Visual Basic macros)
Locus Biosciences
Engineer bacteria-killing bacteriophages with Cas3 nucleases as antibiotic alternatives.
Scientist II, High-throughput Development Team Lead(MAR. 2021 – Present)
• High-throughput development team lead (11-member group); encompasses assay development, Hamilton automation engineering, automation operators, and related bioinformatics.
• Operations project lead to re-vamp organization using Lean Sigma 6 principles across four laboratories and two warehouse areas to maximize functional space and process efficiency. Successfully increased lab personnel capacity by 50% (11 individuals) through strategic space optimization.
• Selected as the unblinded scientist and subject matter expert for CROs during the Phase 2/3 ELIMINATE crPhage clinical trial
• Engineering product lead for CRISPR bacteriophage (crPhage) product to treat Klebsiella pneumoniae infections in partnership with CARB-X.
• Inter-department project lead for a major CapEx investment of $1.2 million to facilitate the automation of bacteriophage engineering. Lead author of project initiation form (PIF) and project charter.
• Completed the 9-week LEAD management program through the NextGen Center. Successful manager of 9 direct reports ranging from Research Technicians to Scientist IIs. Heavily involved in hiring process and acted as hiring manager for a scientist level position.
• Developed ELISA to quantify protein expression in murine and in vitro models
• Experience with all major forms of sequencing (Sanger, Illumina NGS, PacBio long read, ONR MinION). Led acquisition of PacBio Sequel IIe and personally optimized process for high-throughput gDNA extraction for NGS.
Scientist I (Nov. 2019 – FEB. 2021)
• Engineering project lead for the revision of the lead clinical CRISPR bacteriophage (crPhage) product to treat Escherichia coli urinary tract infections in partnership with BARDA.
• Implemented new DNA cloning and bacteriophage engineering strategies that reduced complexity and circumvented roadblocks. Listed inventor on two pending patents related to crPhage.
• Led a request for proposal (RFP) to identify a DNA synthesis vendor and managed vendor relationship to present. One outcome of this outsourcing was a year-over-year 10-fold increase in DNA constructs produced with a 6-fold reduction in cost per unit.